|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CACNA2D3 |
Gene summary for CACNA2D3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CACNA2D3 | Gene ID | 55799 |
| Gene name | calcium voltage-gated channel auxiliary subunit alpha2delta 3 | |
| Gene Alias | HSA272268 | |
| Cytomap | 3p21.1-p14.3 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q8IZS8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55799 | CACNA2D3 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 8.05e-31 | 1.05e+00 | -0.2116 |
| 55799 | CACNA2D3 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 1.77e-11 | 9.39e-01 | -0.1941 |
| 55799 | CACNA2D3 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 2.15e-08 | 7.08e-01 | -0.2107 |
| 55799 | CACNA2D3 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.83e-27 | 1.02e+00 | -0.2119 |
| 55799 | CACNA2D3 | HTA12-15-2 | Human | Pancreas | PDAC | 2.98e-11 | 6.99e-01 | 0.2315 |
| 55799 | CACNA2D3 | HTA12-23-1 | Human | Pancreas | PDAC | 2.93e-09 | 7.86e-01 | 0.3405 |
| 55799 | CACNA2D3 | HTA12-25-1 | Human | Pancreas | PDAC | 2.04e-11 | 8.47e-01 | 0.313 |
| 55799 | CACNA2D3 | HTA12-26-1 | Human | Pancreas | PDAC | 5.15e-35 | 1.33e+00 | 0.3728 |
| 55799 | CACNA2D3 | HTA12-29-1 | Human | Pancreas | PDAC | 2.26e-39 | 1.08e+00 | 0.3722 |
| 55799 | CACNA2D3 | HTA12-30-1 | Human | Pancreas | PDAC | 2.27e-04 | 9.84e-01 | 0.3671 |
| 55799 | CACNA2D3 | HTA12-32-1 | Human | Pancreas | PDAC | 1.46e-03 | 7.06e-01 | 0.3624 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006816 | Lung | AIS | calcium ion transport | 58/1849 | 422/18723 | 6.08e-03 | 4.98e-02 | 58 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0401021 | Lung | AIS | MAPK signaling pathway | 57/961 | 302/8465 | 6.41e-05 | 9.43e-04 | 6.03e-04 | 57 |
| hsa0541221 | Lung | AIS | Arrhythmogenic right ventricular cardiomyopathy | 21/961 | 77/8465 | 9.05e-05 | 1.18e-03 | 7.57e-04 | 21 |
| hsa049212 | Lung | AIS | Oxytocin signaling pathway | 34/961 | 154/8465 | 9.12e-05 | 1.18e-03 | 7.57e-04 | 34 |
| hsa054142 | Lung | AIS | Dilated cardiomyopathy | 22/961 | 96/8465 | 9.02e-04 | 7.11e-03 | 4.55e-03 | 22 |
| hsa054102 | Lung | AIS | Hypertrophic cardiomyopathy | 20/961 | 90/8465 | 2.25e-03 | 1.37e-02 | 8.80e-03 | 20 |
| hsa0401031 | Lung | AIS | MAPK signaling pathway | 57/961 | 302/8465 | 6.41e-05 | 9.43e-04 | 6.03e-04 | 57 |
| hsa0541231 | Lung | AIS | Arrhythmogenic right ventricular cardiomyopathy | 21/961 | 77/8465 | 9.05e-05 | 1.18e-03 | 7.57e-04 | 21 |
| hsa049213 | Lung | AIS | Oxytocin signaling pathway | 34/961 | 154/8465 | 9.12e-05 | 1.18e-03 | 7.57e-04 | 34 |
| hsa054143 | Lung | AIS | Dilated cardiomyopathy | 22/961 | 96/8465 | 9.02e-04 | 7.11e-03 | 4.55e-03 | 22 |
| hsa054103 | Lung | AIS | Hypertrophic cardiomyopathy | 20/961 | 90/8465 | 2.25e-03 | 1.37e-02 | 8.80e-03 | 20 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CACNA2D3 | SNV | Missense_Mutation | c.292N>T | p.Met98Leu | p.M98L | Q8IZS8 | protein_coding | deleterious(0.01) | benign(0.175) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CACNA2D3 | SNV | Missense_Mutation | c.1646N>T | p.Arg549Leu | p.R549L | Q8IZS8 | protein_coding | tolerated(0.17) | possibly_damaging(0.757) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| CACNA2D3 | SNV | Missense_Mutation | c.3038T>C | p.Val1013Ala | p.V1013A | Q8IZS8 | protein_coding | tolerated(0.08) | benign(0.059) | TCGA-AR-A1AU-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| CACNA2D3 | SNV | Missense_Mutation | novel | c.2482N>A | p.Gln828Lys | p.Q828K | Q8IZS8 | protein_coding | deleterious(0.01) | benign(0.23) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CACNA2D3 | SNV | Missense_Mutation | rs555199325 | c.731N>A | p.Arg244Gln | p.R244Q | Q8IZS8 | protein_coding | deleterious(0.01) | probably_damaging(0.966) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
| CACNA2D3 | SNV | Missense_Mutation | c.1171C>T | p.Arg391Cys | p.R391C | Q8IZS8 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-C8-A12M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CACNA2D3 | SNV | Missense_Mutation | c.3151N>T | p.Arg1051Cys | p.R1051C | Q8IZS8 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-C8-A12W-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| CACNA2D3 | SNV | Missense_Mutation | novel | c.517N>A | p.Gln173Lys | p.Q173K | Q8IZS8 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CACNA2D3 | insertion | In_Frame_Ins | novel | c.1461_1462insGCCTCAGAAATTTCTCCTTTGTGTGGATTGTAC | p.Gln487_Asn488insAlaSerGluIleSerProLeuCysGlyLeuTyr | p.Q487_N488insASEISPLCGLY | Q8IZS8 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CACNA2D3 | SNV | Missense_Mutation | novel | c.2022G>T | p.Lys674Asn | p.K674N | Q8IZS8 | protein_coding | tolerated(0.3) | possibly_damaging(0.63) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 55799 | CACNA2D3 | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL1200382 | BEPRIDIL HYDROCHLORIDE | |
| 55799 | CACNA2D3 | ION CHANNEL, DRUGGABLE GENOME | celecoxib | CELECOXIB | 22336956 | |
| 55799 | CACNA2D3 | ION CHANNEL, DRUGGABLE GENOME | modulator | CHEMBL593430 | ATAGABALIN | |
| 55799 | CACNA2D3 | ION CHANNEL, DRUGGABLE GENOME | modulator | CHEMBL1059 | PREGABALIN | |
| 55799 | CACNA2D3 | ION CHANNEL, DRUGGABLE GENOME | modulator | CHEMBL1628502 | GABAPENTIN ENACARBIL | |
| 55799 | CACNA2D3 | ION CHANNEL, DRUGGABLE GENOME | modulator | CHEMBL2103836 | IMAGABALIN | |
| 55799 | CACNA2D3 | ION CHANNEL, DRUGGABLE GENOME | modulator | CHEMBL940 | GABAPENTIN |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |